SciELO - Scientific Electronic Library Online

vol.33 número4Cáncer de próstata: práctica clínica basada en la evidencia índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google


Actas Urológicas Españolas

versión impresa ISSN 0210-4806


VILAR GONZALEZ, Santiago et al. Review of current treatment for hot flushes induced by androgen deprivation in prostate carcinoma. Actas Urol Esp [online]. 2009, vol.33, n.4, pp.337-343. ISSN 0210-4806.

Considering the currently increased incidence, prevalence and survival of prostate cancer, the management of hot flushes associated with LH-RH analog treatment must be taken into account. The most widely used and effective treatment is hormone replacement, though the latter is not without risks. It is presently possible to address hot flushes in these patients based on a broad range of treatment options in which hormone therapy may constitute a last option, due to the risk of tumor relapse or progression - since prostate cancer is hormone sensitive. The present study reviews the currently used treatments and hygiene-dietary measures that may help reduce the symptoms. A review is made of both hormone and non-hormone therapies, based on the existing scientific evidence. Drugs such as the new antidepressants, gabapentin and clonidine may play an important role in the management of hot flushes. While the underlying mechanisms of action are varied, they are related to the complex feedback exerted by the sexual hormones upon the hypothalamic secretion of noradrenalin - this being the principal etiological factor of hot flushes.

Palabras clave : Prostate carcinoma; Hot flushes; Hormone deprivation; Treatment; Antidepressants; Clonidine; Gabapentin; Hormone replacement therapy.

        · resumen en Español     · texto en Español     · Español ( pdf )


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons